Wits University on Tuesday said that it was beginning clinical trials for the first African COVID-19 vaccine on Wednesday.
The announcement was made during a virtual press conference hosted by the university.
The institution said that 2,000 people between the ages of 18 and 65 would be enrolled for the trial, which was expected to be run at multiple sites in South Africa.
This would be through a collaboration with the University of Oxford and the Oxford Jenner Institute on the South African trial. The South African Medical Research Council (SAMRC) has partnered with the Bill Gates Foundation to develop the vaccine.
Professor of Vaccinology at Wits University and director of SAMRC’s Vaccines and Infectious Diseases Analytics (VIDA) Research Unit, Shabir Madhi, is leading the South African Ox1Cov-19 Vaccine VIDA-Trial.
“This is a landmark moment for South Africa and Africa at this stage of the COVID-19 pandemic. As we enter winter in South Africa and pressure increases on public hospitals, now more than ever we need a vaccine to prevent infection by COVID-19,” said Madhi at the launch of the South African Ox1Cov-19 Vaccine VIDA-Trial.
“We began screening participants for the South African Oxford 1 COVID-19 vaccine trial last week and the first participants will be vaccinated this week,” he added.
More Stories
Zuma Medical Parole Appeal To Be Heard In August
Saftu Warns That SA On A Fast March To Becoming A Failed State
Ramaphosa Reiterates Importance Of African Unity
NICD Reports 5 284 New COVID-19 Cases In SA
Five VBS-linked Suspects Appear In Orkney Magistrate’s Court
Green Energy To Form Key Part Of SA-Germany Partnership
Umdloti Residents Protest Against Property Developers
NICD Reports 4 227 New COVID-19 Cases In SA
SANDF Will Be Hard-Pressed To Assist In Future Catastrophes In SA – Modise
Alleged Parliament Arsonist Zandile Mafe’s Bail Application To Be Heard Again
Golden Arrows Opts Not To Hike Bus Fares For Now
German Chancellor Olaf Scholz Visits South Africa